Literature DB >> 11388508

Use of the recombinant K39 dipstick test and the direct agglutination test in a setting endemic for visceral leishmaniasis in Nepal.

C Bern1, S N Jha, A B Joshi, G D Thakur, M B Bista.   

Abstract

We evaluated the field use of two serologic tests for visceral leishmaniasis (VL), the direct agglutination test (DAT) and rK39 dipstick test, in the context of a case-control study. Most VL cases in Nepal are currently diagnosed on clinical grounds and with relatively non-specific tests such as the formol-gel test. Among 14 newly diagnosed VL patients with bone-marrow slides confirmed positive in two independent laboratories, the sensitivity of both tests was 100%. Among 113 controls with no personal or household history of VL, the specificity of the rK39 was 100% while that of the DAT was 93%. The rK39 was less expensive than DAT, and has the advantages of ease of use and obtaining results within minutes. The wider use of the rK39 dipstick test could improve the specificity of VL diagnosis in Nepal.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11388508     DOI: 10.4269/ajtmh.2000.63.153

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  24 in total

Review 1.  Laboratory diagnosis of visceral leishmaniasis.

Authors:  Shyam Sundar; M Rai
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 2.  Diagnosis of visceral leishmaniasis: developments over the last decade.

Authors:  Gurumurthy Srividya; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Parasitol Res       Date:  2011-11-09       Impact factor: 2.289

3.  Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal.

Authors:  Siddhivinayak Hirve; Shri Prakash Singh; Narendra Kumar; Megha Raj Banjara; Pradeep Das; Shyam Sundar; Suman Rijal; Anand Joshi; Axel Kroeger; Beena Varghese; Chandreshwar Prasad Thakur; M Mamun Huda; Dinesh Mondal
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

4.  Evaluation of two rK39 dipstick tests, direct agglutination test, and indirect fluorescent antibody test for diagnosis of visceral leishmaniasis in a new epidemic site in highland Ethiopia.

Authors:  Carmen Cañavate; Merce Herrero; Javier Nieto; Israel Cruz; Carmen Chicharro; Pilar Aparicio; Abate Mulugeta; Daniel Argaw; Anna J Blackstock; Jorge Alvar; Caryn Bern
Journal:  Am J Trop Med Hyg       Date:  2011-01       Impact factor: 2.345

5.  Potential of direct agglutination test based on promastigote and amastigote antigens for serodiagnosis of post-kala-azar dermal leishmaniasis.

Authors:  Ruchi Singh; B V Subba Raju; R K Jain; Poonam Salotra
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

6.  Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins.

Authors:  Yasuyuki Goto; Rhea N Coler; Jeffrey Guderian; Raodoh Mohamath; Steven G Reed
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  A new molecular surveillance system for leishmaniasis.

Authors:  Kishor Pandey; Basu Dev Pandey; Arun Kumar Mallik; Jyoti Acharya; Kentaro Kato; Osamu Kaneko; Pedro Eduardo Ferreira
Journal:  Am J Trop Med Hyg       Date:  2014-04-21       Impact factor: 2.345

8.  Field Adaptable Tests for Kala-Azar.

Authors:  V K Agrawal
Journal:  Med J Armed Forces India       Date:  2011-07-21

9.  Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen.

Authors:  Sarman Singh; Veena Kumari; Niti Singh
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

10.  Significance of persistence of antibodies against Leishmania infantum in Sicilian patients affected by acute visceral leishmaniasis.

Authors:  Pasquale Mansueto; Ilenia Pepe; Aurelio Seidita; Francesca Scozzari; Giustina Vitale; Francesco Arcoleo; Inglese Elvira; Enrico Cillari; Giovam Battista Rini; Nicola Napoli; Salvatore Di Rosa; Serafino Mansueto; Gaetana Di Fede
Journal:  Clin Exp Med       Date:  2011-06-29       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.